CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [*****] indicates the redacted confidential portions of this...And Distribution Agreement • February 26th, 2020 • Kamada LTD • Pharmaceutical preparations
This SIXTH Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement dated August 23rd, 2010 as amended on September 6th, 2012, May 14th, 2013, February 15th, 2014, August 25th, 2015, and September 30th, 2016, by and between Baxalta US Inc., a member of the Takeda group of companies, having a place of business at 1200 Lakeside Dr., Bannockburn, IL 60015, USA (hereinafter “Baxalta”) and Kamada Ltd., having a place of business at 2 Holzman Street, Weizmann Science Park, Rehovot 7670402, Israel (hereinafter “Kamada”) (the “Agreement”) is entered into as of this 30th day of August, 2019 (the “Effective Date”). Baxalta and Kamada shall collectively be referred to as the “Parties”.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [*****] indicates the redacted confidential portions of this...Clinical Study Supply Agreement • February 26th, 2020 • Kamada LTD • Pharmaceutical preparations
This Clinical Study Supply Agreement (the “CSSA”) is made effective as of May 8th, 2019 (the “CSSA Effective Date”) by and between KAMADA Ltd., an Israeli company, with a principal place of business at 2 Holzman St., Science Park, P.O. Box 4081, Rehovot, 7670402, Israel (“KAMADA”) and PARI Pharma GmbH, with its registered office at Moosstrasse 3, 82319 Starnberg, Germany (“PARI”). In this CSSA, either PARI or KAMADA is referred to as a “Party,” and collectively as the “Parties.”
